Tag: shares

NEWTOWN, Pa., June 04, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the pricing of its public offering of an aggregate of 2,768,600 shares of its Class A common stock (or common stock equivalents), and warrants to purchase up to 2,768,600 shares of common stock, at a combined public offering price of $3.27 per share and accompanying warrants.

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Cerevel Therapeutics Holdings, Inc. (CERE) on behalf of long-term stockholders following a class action complaint that was filed against Cerevel on April 3, 2025 with a Class Period from October 11, 2023 through August 1, 2024. Our investigation concerns whether the board of directors of Cerevel have breached their fiduciary duties to the company.

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) on behalf of Tempus stockholders. Our investigation concerns whether Tempus has violated the federal securities laws and/or engaged in other unlawful business practices.

THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, RUSSIA, BELARUS, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” IN THE END OF THIS PRESS RELEASE.

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.


Frøya, 5 June 2025: Reference is made to the stock exchange release from Kaldvík AS (the "Company") published on 4 June 2025 regarding a contemplated private placement to raise gross proceeds of the NOK equivalent of approximately EUR 46.2 million (the "Private Placement") by the issuance of new shares in the Company (the "Offer Shares"). The Company hereby announces that it has raised approximately NOK 532 million, equivalent to approximately EUR 46.2 million, in gross proceeds through a private placement of 38,011,050 new shares (the "New Shares") at a price per share of NOK 14 (the "Offer Price"). The Private Placement took place through an accelerated bookbuilding process managed by DNB Carnegie, a part of DNB Bank ASA ("DNB Carnegie") as Sole Global Coordinator and Joint Bookrunner and Arion Banki hf ("Arion") and Nordea Bank Abp, filial i Norge ("Nordea") as Joint Bookrunners for the Private Placement (jointly, the "Managers").

MISSISSAUGA, Ontario, June 04, 2025 (GLOBE NEWSWIRE) -- KP Tissue Inc. (“KPT” or the “Company”) (TSX:KPT) is pleased to announce that both Institutional Shareholder Services (“ISS”) and Glass Lewis & Co. (“Glass Lewis”), two leading independent proxy advisory firms, have recommended that KPT shareholders ("Shareholders") vote FOR all resolutions at the upcoming Annual Meeting of Shareholders (the "Meeting").

BOSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on June 2, 2025, the Compensation Committee of Praxis’ Board of Directors granted a restricted stock unit award covering 750 shares of its common stock to one new non-executive employee under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit award was granted as inducement material to the employee’s entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

Highlights

Investors can contact the law firm at no cost to learn more about recovering their losses

IOVA Investors with Losses Encouraged to Contact Hagens Berman

CODI Investors with Losses Encouraged to Contact Hagens Berman